A novel bispecific aptamer targeting LAG3 and HER2 enhances T cell-mediated immunotherapy against HER2-positive cancer cells
Our findings demonstrate that HLB-apt exerts dual antitumor effects likely through simultaneously targeting LAG3 on T cells and HER2 on tumor cells, facilitating T cell recruitment and potentially interfering with immune checkpoint pathways. Therapeutic efficacy was markedly enhanced in tumor-bearing mice receiving combined HLB-apt and Jurkat cell administration, This HLB-apt holds promising clinical potential for malignancies characterized by HER2 overexpression.
Authors
- Zufa Sabeel
- Yiyang Dong (ORCID: https://orcid.org/0000-0003-1752-3935)
- Jian Dong (ORCID: https://orcid.org/0000-0002-9941-1015)
- Ying Lü (ORCID: https://orcid.org/0000-0002-7698-8962)
- Yang Zhao (ORCID: https://orcid.org/0000-0002-1428-5145)
- Wenjing Zhang (ORCID: https://orcid.org/0000-0003-4911-372X)
- Xiaoyang Chen (ORCID: https://orcid.org/0000-0002-7356-8129)
- Rui Guo (ORCID: https://orcid.org/0000-0001-8684-1414)
- Lianhui Zhao
Institutions
- Beijing University of Chemical Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1557910
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09